Did you know that your version of Internet Explorer is out of date?
To get the best possible experience using our website we recommend downloading one of the below web browsers.

Internet Explorer 9, Firefox, Chrome, or Safari.

Treatment Access News

New HCV medication Elbasvir/Grazoprevir marketed as "Zepatier" receives its Notice of Compliance from Health Canada

january 22, 2016

Elbasvir/Grazoprevir (Zepatier) is a hepatitis C medication that treats G1 and G4 but can also treat G3 when used with sofosbuvir. 

Note that there’s still a place for ribavirin for prior-treatment-failures. This is consistent with most new DAAs, but it bears repeating that while we appear to be clearly out of the Interferon era, there is no timeline for ribavirin’s exit, as it continues to show therapeutic benefit to harder-to-treat patients.

The Zepatier NOC in Canada is the first in the world.  

This is another great pan-genotypic option. For some the treatment duration is a low as 8 weeks.  

We are pleased  that HIV/HCV co-infected patients were included in the drugs clinical trials.

View the product monograph.

Learn more about the Common Drug Review in the video below.